<div id="readability-page-1"><div>Biocon is stepping up its hunt for in-licensing deals to fast-track growth in its biosimilars business, betting that partnerships can plug portfolio gaps without the long gestation of in-house development.“We are on the active lookout,” chief executive officer and managing director Shreehas Tambe told media, underlining that the company has already built a global commercial footprint and can now add external assets that are “synergistic” to its portfolio.After years of heavy investment in building scale and R&amp;D capabilities, Biocon is now looking to leverage its commercial platform more efficiently, including by bringing in products it doesn’t develop.Biocon, which completed the integration of Viatris' global biosimilars business in December 2023, has a commercial presence in advanced markets, including the US, Europe, Canada, Japan, Australia, and over 70 emerging markets.Biocon Biologics acquired Viatris' biosimilar business in November 2022 for $3.335 billion.The company has commercialised 12 biosimilar products globally and serves over 6.5 million patients annually, it said. The company maintains a robust pipeline of over 20 biosimilar assets. But the company is looking for more.Biosimilars are low cost are identical copies of biologic medicines, which are developed after the original biologic patent expires. They are used for treating diseases like cancer and autoimmune disorders.Why in-licensing matters nowFor a biosimilars player, time is critical. Developing a biosimilar can take years and significant capital; missing the launch window when patents expire can mean losing first-mover advantage.That’s where in-licensing fits in. By acquiring or partnering on near-market or approved assets, Biocon can accelerate launches, deepen therapy presence and improve asset utilisation.Tambe pointed to this logic — if the company has strength in a therapy area but lacks a specific molecule, it would “be happy to bring it in” to complete the portfolio and drive it through its commercial network.Biocon has already used it selectively. Tambe cited Etanercept biosimilar as an example of using an in‑licensing partnership to strengthen its portfolio.“Look at the opportunity we’ve got with Etanercept where we brought that product in because we’re not developing ourselves, but we needed that product to complete the portfolio… and now we have a commercial front end which can drive the product,” he said. Etanercept is used to treat autoimmune and inflammatory conditions such as rheumatoid arthritis and psoriasis.Biosimilars remain Biocon's growth engine. The segment generated Rs 10,431 crore in FY26 revenue, growing 16 percent year-on-year, with EBITDA margins around 26 percent.Tambe said recent launches are beginning to scale, with multiple products expected to drive growth in the coming quarters. He doesn't see a reason why the EBITDA margins biosimilar business can rise to 30 percent in the coming quarters.The shift toward in-licensing also mirrors where Biocon is in its lifecycle.“Major investment phase is substantially behind us,” Tambe said, adding the focus is now on improving capacity utilisation, margins and return on capital.The push for partnerships comes as the biosimilars space becomes more crowded globally. Tambe acknowledged rising competition but claimed that Biocon retains an edge due to early investments and capability leadership in complex biologics. Still, speed-to-market and portfolio breadth are becoming key differentiators—making external deal-making more important.As Tambe put it, the strategy is simple - identify gaps, plug them quickly, and use Biocon’s global commercial engine to scale.</div></div>

暉致

納斯達克生物科技指數 ETF - iShares Nasdaq

醫療業 ETF - Vanguard

Biocon 正在積極尋求引進許可交易，以增強其生物仿製藥業務，旨在填補產品組合的空白，而無需耗時的內部開發。首席執行官 Shreehas Tambe 強調了公司在全球的成熟市場地位以及對協同外部資產的需求。在整合了 Viatris 的生物仿製藥業務後，Biocon 已商業化 12 款生物仿製藥，並在其管道中有超過 20 款。該戰略專注於加速產品上市和提高資產利用率，以應對競爭激烈的市場，目標是在未來幾個季度將 EBITDA 利潤率提高至 30%

Biocon 尋求通過許可協議來加速生物仿製藥的增長